How Long Can You Safely Stay on Menopausal Hormone Therapy?

The "5-Year Rule" Is Outdated

No major medical society currently endorses a blanket 5-year limit on menopausal hormone therapy. That idea became widespread after early reporting of the Women's Health Initiative (WHI) in 2002, but subsequent reanalysis and two decades of follow-up data have reshaped clinical thinking. The Menopause Society's 2022 hormone therapy position statement explicitly states that "arbitrary limits on duration should not be imposed" and that treatment should continue as long as benefits outweigh risks for the individual patient [1].

The WHI combined estrogen-progestin arm was halted at a median of 5.6 years due to a small increase in breast cancer incidence (hazard ratio 1.26, or roughly 8 additional cases per 10,000 women per year) [2]. That number became the basis for rigid time caps. What received less attention: the estrogen-only arm in hysterectomized women ran for 7.2 years and showed no increase in breast cancer risk, with a hazard ratio of 0.77 that actually favored estrogen [3]. The distinction between estrogen alone and estrogen plus a progestin matters enormously when counseling patients about duration.

The International Menopause Society (IMS) echoed this in its 2016 recommendations, noting that "there is no reason to place mandatory limitations on the duration of HRT" provided that the prescriber and patient review the indication regularly [4]. A yearly reassessment is the standard, not a predetermined stop date.

What the WHI Actually Showed About Long-Term Risk

The WHI remains the largest randomized controlled trial of MHT, enrolling 27,347 postmenopausal women across two arms. Understanding its results by subgroup is necessary for any duration discussion. The headline finding of increased cardiovascular events applied primarily to women who were older than 60 or more than 10 years past menopause at study entry [2].

Among women aged 50 to 59, estrogen-only therapy was associated with a significantly lower coronary artery calcium score after 7.4 years of follow-up, suggesting a cardioprotective effect when started early [5]. The 18-year cumulative follow-up published in JAMA in 2017 confirmed that all-cause mortality did not differ between the hormone and placebo groups in either trial arm (HR 0.99 for estrogen-progestin; HR 1.01 for estrogen-only) [6]. No excess deaths. That finding has been called "reassuring" by The Menopause Society [1].

Breast cancer risk in the combined arm did persist after discontinuation, with the 20-year follow-up showing a hazard ratio of 1.28 for breast cancer in the estrogen-plus-progestin group [7]. The absolute risk, however, remained modest: fewer additional cases than those attributable to two glasses of wine per day or obesity after menopause. Estrogen-only users still had no excess breast cancer risk at 20 years.

The "Timing Hypothesis" and Why It Changes the Duration Conversation

The timing hypothesis (also called the "window of opportunity") holds that MHT confers cardiovascular benefit when initiated close to menopause but may increase risk when started in older women with established atherosclerosis. The ELITE trial provided direct evidence: oral estradiol slowed carotid intima-media thickness progression in women who were fewer than 6 years from menopause but had no effect in women who were 10 or more years past menopause [8].

This has practical implications for duration. A woman who starts MHT at 51 may safely continue for 10 to 15 years (or longer) and still be within the favorable cardiovascular window, particularly if she uses transdermal estradiol and micronized progesterone rather than older oral conjugated estrogens and medroxyprogesterone acetate. The Endocrine Society's 2015 scientific statement on MHT supports this age-stratified approach, recommending that clinicians consider the patient's time since menopause rather than chronological age alone [9].

Dr. JoAnn Manson, principal investigator of the WHI and professor at Harvard Medical School, has stated: "For women with bothersome menopausal symptoms who are in their 50s and within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks, and there should not be arbitrary time limits placed on use" [1].

Formulation Matters for Long-Term Safety

Not all hormone therapy carries identical risk. The type of estrogen, the route of delivery, and the choice of progestogen each affect the safety profile over time.

Transdermal vs. oral estrogen. Oral estrogens undergo first-pass hepatic metabolism, which increases clotting factor production. The ESTHER study (a French case-control study) found that oral estrogen roughly quadrupled venous thromboembolism (VTE) risk, while transdermal estradiol at doses up to 50 mcg/day showed no significant increase in VTE risk (odds ratio 0.9) [10]. For women planning extended use, transdermal patches or gels lower one of the primary safety concerns.

Micronized progesterone vs. synthetic progestins. The E3N cohort study followed over 80,000 French women and found that estrogen combined with micronized progesterone carried no significant increase in breast cancer risk over a mean follow-up of 8.1 years (relative risk 1.00), whereas synthetic progestins were associated with a relative risk of 1.69 [11]. This distinction informs duration guidance: a woman on transdermal estradiol plus micronized progesterone has a different risk trajectory than one on oral conjugated estrogen plus medroxyprogesterone.

Low-dose and ultra-low-dose formulations. Standard-dose oral conjugated estrogen is 0.625 mg; low-dose is 0.3 mg or 0.45 mg. Transdermal patches range from 0.025 mg to 0.1 mg per day. The Menopause Society recommends using the lowest effective dose, particularly in women continuing MHT past age 60 [1]. Dose reduction can preserve symptom relief while minimizing estrogen exposure over decades of use.

Bone Health: A Reason Some Women Stay on MHT Indefinitely

MHT is the only therapy proven to reduce fractures at all skeletal sites. The WHI showed a 34% reduction in hip fractures and a 24% reduction in total fractures during active use of combined estrogen-progestin [12]. Bone loss resumes within 1 to 2 years of discontinuation, and the protective effect is largely lost within 5 years of stopping [13].

For women with osteoporosis or high fracture risk who cannot tolerate bisphosphonates or denosumab, extended MHT may be medically appropriate specifically for skeletal protection. The Endocrine Society acknowledges MHT as a first-line option for fracture prevention in postmenopausal women under 60, and ongoing use beyond that age can be justified when alternative therapies are contraindicated or poorly tolerated [14].

Dr. Stephanie Faubion, medical director of The Menopause Society, has noted: "For some women, particularly those at high risk of fracture, hormone therapy may be continued longer term with appropriate monitoring, because no other therapy provides the same breadth of skeletal benefit" [1].

Who Should Reconsider Extended Use

Certain conditions shift the risk-benefit ratio against long-term MHT. Absolute contraindications include a personal history of hormone receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, and known thrombophilic disorders with prior VTE [1]. Women with a history of cardiovascular events (myocardial infarction, stroke) after age 60 should not initiate or continue systemic MHT [9].

Relative concerns that warrant closer monitoring during extended use include a strong family history of breast cancer (particularly BRCA1/2 carriers), elevated baseline cardiovascular risk (hypertension, diabetes, smoking), a history of migraine with aura (which raises stroke risk with oral estrogen), and gallbladder disease. Each of these factors requires individual weighing rather than a blanket prohibition.

The decision to continue, reduce, or stop MHT should be revisited every 12 months. This annual review should include a symptoms assessment, a mammogram, blood pressure measurement, and a discussion of the patient's quality of life on versus off therapy [1]. Some women attempt dose tapering or a trial discontinuation every few years to test whether symptoms have resolved. About 50% of women who try stopping MHT will experience a return of vasomotor symptoms [15].

How to Approach Tapering and Discontinuation

There is no consensus on whether abrupt cessation or gradual tapering is better. No randomized trial has demonstrated that tapering reduces symptom recurrence compared to stopping outright. In practice, many clinicians reduce the dose by half for 3 to 6 months and then discontinue, simply to ease the transition.

Symptom recurrence after stopping varies widely. The SWAN study found that the median total duration of vasomotor symptoms is 7.4 years from onset, though some women experience hot flashes for more than a decade [15]. A woman who started MHT at age 51 and stops at 56 may still have 2 to 3 years of symptoms ahead. This biological reality means that many women restart therapy after a trial off it.

If a woman discontinues MHT for bone health reasons, a transition to a bisphosphonate or denosumab should be considered to prevent the rapid bone loss that follows estrogen withdrawal. Alendronate 70 mg weekly or risedronate 150 mg monthly are common sequential options. Without a bone-protective agent, spine and hip BMD can decline by 2% to 6% in the first year after stopping estrogen [13].

What "Indefinite" Use Looks Like in Practice

Some women continue MHT into their 70s and beyond. This is neither common nor universally recommended, but it is not automatically unsafe. The key is that these women typically use low-dose transdermal estradiol (0.025 mg patch or equivalent gel), have been on therapy continuously since the perimenopause, and have no contraindications that have developed over time.

A 2023 Menopause Society advisory reaffirmed that for women over 65 who have been on MHT long-term and wish to continue, the decision should be shared between patient and clinician, informed by the patient's symptom burden, bone density, cardiovascular risk profile, and breast cancer risk [16]. Discontinuation should never be forced solely because a woman has crossed an age threshold.

Monitoring for extended users (those on MHT for 10 or more years) should include annual mammography and clinical breast exam, periodic lipid panels and fasting glucose, DEXA scan every 2 to 3 years if bone health is a primary indication, blood pressure monitoring at every visit, and discussion of family history changes that might alter breast cancer risk.

The conversation around stopping should always center on what the patient values. A woman whose quality of life is severely compromised by vasomotor symptoms may reasonably accept a small incremental risk of breast cancer. Another woman with moderate symptoms and a first-degree relative with breast cancer may choose to taper at 5 years. Both decisions can be correct.

Emerging Data on Ultra-Long-Term Outcomes

The WHI's 18-year cumulative follow-up (published in JAMA, 2017) provided the longest post-trial mortality data for any MHT trial. During the combined intervention and post-intervention phases, all-cause mortality was not increased for either the estrogen-plus-progestin group (HR 1.02; 95% CI, 0.96 to 1.08) or the estrogen-only group (HR 0.94; 95% CI, 0.88 to 1.01) [6]. Cancer mortality, cardiovascular mortality, and total mortality were similar across treatment and placebo arms.

The Danish Osteoporosis Prevention Study (DOPS) offered complementary long-term evidence. In that open-label trial, women randomized to HRT within 2 years of menopause and treated for 10 years had a significantly lower composite risk of death, heart failure, and myocardial infarction at 16-year follow-up (HR 0.61 to 95% CI 0.39 to 0.94), with no increase in cancer, VTE, or stroke [17].

These datasets suggest that for appropriately selected women who start early and use modern formulations, MHT measured in decades does not produce the harms that were feared in 2002. The clinical task is not to set a timer but to reassess regularly and respond to each woman's evolving risk profile.

Annual mammography with tomosynthesis remains the standard surveillance tool during MHT use, per American Cancer Society guidelines [18].